Modern Radiotherapy and Innovative Drugs for Cancer Care
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: closed (15 July 2024) | Viewed by 465
Special Issue Editor
2. Department of Radiation Oncology, Henri Mondor University Hospital & Henri Mondor Breast Cancer Center, 94000 Créteil, France
Interests: modern radiotherapy; innovations; radiobiology; new drugs; combined therapy; toxicity; stereotactic radiation therapy; oligometatasis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Radiotherapy is one of the major treatments in Oncology. About 60% of cancer patients will receive radiation therapy during the course of their disease. Radiation therapy can be curative or palliative depending on the disease stage and treatment objective.
During the last decades, radiotherapy has made considerable progress driven by transformational development in technology and informatics to the point that the old paradigm of “maximal tolerable treatment” has shifted to “minimal effective treatment”. This conceptual revolution has made it possible to drastically reduce or sometimes eliminate the majority of acute and late toxicities. However, other radiation effects, such as secondary cancers, remain an unavoidable problem mainly due to the direct mutagenic effect of ionizing radiation and the inherent individual radiosensitivity. Nevertheless, these risks have tremendously decreased lately due to widespread implementation of normal tissue constraints and the quality control programs and processes that have become the golden rules in modern radiotherapy departments.
In parallel with the recent advances in radiotherapy, we have witnessed the development of many novel molecules and drugs that were able to transform the natural history of certain cancer types. The improvement of patient survival brought by these drugs makes it possible to consider new regimens combining these drugs with radiation. However, due to our lack of knowledge on the synergistic effects of these combinations and their long-term consequences, their clinical use and timing of administration in combination with radiation remains a daily challenge.
This special issue discusses the potential benefits and risks of modern radiotherapy regimens using very high doses to small targets in patients with oligometastatic disease. It also reviews new radiation techniques delivering highly conformal doses, and studies combining promising new combination of radiation with novel systemic therapies using different timing of administration.
Prof. Dr. Yazid Belkacémi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- modern radiotherapy
- innovations
- radiobiology
- new drugs
- combined therapy
- toxicity
- steretoctic radiation therapy
- oligometatasis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
